Elicio Therapeutics, Inc. has released its third-quarter results for 2026, marking a significant moment for the company as it continues to advance its pharmaceutical pipeline. The report, filed on November 5, 2026, highlights the company's ongoing commitment to innovation in the pharmaceutical preparations sector.

Founded as a life sciences company, Elicio Therapeutics operates under the Standard Industrial Classification (SIC) code 2834, which pertains to Pharmaceutical Preparations. The company is listed on the Nasdaq under the ticker symbol ELTX and has its headquarters in Boston, Massachusetts.

The latest filing reveals that Elicio is actively working on its product development and has made strides in its clinical programs. Specific financial figures and operational details were not disclosed in the filing, but the company continues to demonstrate its potential in the competitive pharmaceutical landscape.

This update may affect various stakeholders, including investors, employees, and healthcare professionals. As Elicio progresses with its therapies, it could influence market dynamics within the pharmaceutical preparations industry, where innovation is key.

Looking ahead, the filing does not specify what actions will follow this report, leaving stakeholders eager for future updates on Elicio's developments.

Financial Overview

While specific financial figures were not detailed in the filing, Elicio Therapeutics reported that it is in a strong position to continue its research and development efforts. The company is incorporated in Delaware and operates under the fiscal year ending on December 31.

Corporate Developments

The filing also notes that Elicio Therapeutics has undergone a name change from Angion Biomedica Corp. as of February 28, 2014, reflecting its strategic shift towards a focus on innovative therapeutic solutions. This rebranding aligns with the company's mission to enhance its visibility in the pharmaceutical sector.

Contact Information

For stakeholders seeking further information, Elicio's business address is 451 D Street, 5th Floor, Boston, MA 02210. They can be reached via phone at (857) 209-0050.

Future Reporting

The filing does not provide insights into upcoming milestones or specific timelines for product launches or clinical trial results, leaving investors and analysts awaiting further updates on Elicio's progress in the pharmaceutical landscape.